Related Experiment Videos
Immunosuppression in patients with metastatic squamous cell carcinoma from the skin
S M Dinehart1, D Z Chu, A W Maners
1Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock.
Abstract:
Sixteen of 70 patients with metastatic squamous cell carcinoma (SCC) from the skin had evidence of clinical immunosuppression. In addition to patients with lymphoproliferative disorders or renal failure, those with cicatricial pemphigoid and those undergoing chronic oral corticosteroid therapy were identified as being at high risk. Host immune surveillance appears to play a major role in determining the metastatic potential of cutaneous SCC.
Insights
Patients with skin cancer (cutaneous squamous cell carcinoma) who are immunosuppressed face higher risks of metastasis. Conditions like cicatricial pemphigoid and corticosteroid use increase this risk, highlighting the role of immune surveillance.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Metastatic cutaneous squamous cell carcinoma (SCC) poses a significant clinical challenge.
- Understanding factors influencing SCC metastasis is crucial for patient outcomes.
Purpose of the Study:
- To investigate the prevalence of clinical immunosuppression in patients with metastatic cutaneous SCC.
- To identify patient groups at higher risk for metastasis.
Main Methods:
- Retrospective analysis of 70 patients with metastatic cutaneous SCC.
- Assessment for clinical evidence of immunosuppression and associated risk factors.
Main Results:
- Sixteen out of 70 patients (22.9%) exhibited clinical immunosuppression.
- High-risk groups included patients with lymphoproliferative disorders, renal failure, cicatricial pemphigoid, and those on chronic oral corticosteroids.
Conclusions:
- Host immune surveillance is a critical factor in the metastatic potential of cutaneous SCC.
- Identifying and managing immunosuppression in at-risk patients may be key to preventing SCC metastasis.